Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 8/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 6/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP7 | P09237 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3058779 | 0.90 | NPSR1 (0.37) | HSD11B1SMN1; SMN2L3MBTL1MMP1MMP3 | |
| SCHEMBL3063678 | 0.88 | L3MBTL1 (0.35) | HSD11B1KMT2AMEN1L3MBTL1MMP1 | |
| SCHEMBL3054705 | 0.85 | NR3C1 (0.37) | HSD11B1PTGDRKMT2AMEN1L3MBTL1 | |
| SCHEMBL3055000 | 0.85 | HSD11B1 (0.43) | HSD11B1KMT2AL3MBTL1 | |
| SCHEMBL3060406 | 0.84 | MMP1 (0.41) | KMT2AMEN1SMN1; SMN2L3MBTL1MMP1 | |
| SCHEMBL3062049 | 0.84 | MMP1 (0.35) | HSD11B1KMT2AMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL3060016 | 0.83 | ACHE (0.39) | HSD11B1PTGDRKMT2AMEN1 | |
| SCHEMBL3055905 | 0.83 | NR3C1 (0.41) | KMT2AMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL3054968 | 0.82 | HSD11B1 (0.40) | HSD11B1KMT2AMEN1L3MBTL1 | |
| SCHEMBL3065979 | 0.81 | SMYD3 (0.37) | HSD11B1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | HSD11B1 136/4885PTGDR 1086/4885PGR 4763/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | HSD11B1 136/4885PTGDR 1086/4885PGR 4763/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | HSD11B1 136/4885PTGDR 1086/4885PGR 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.